Unlocking Europe’s Innovation Potential:…
ASTP's EU Committee reflects on the relevance of the European Strategy on Research and Technology Infrastructures.
In a perfect world of licensing, TTOs may dream of a discovery licensed to a medical company, which continues developing it until it has established proof-of-concept in humans.Then a larger firm with the capability to conduct late-stage clinical trials comes in and carries the molecule to the market launch. It is an ideal scenerio that rarely plays out in real life. Instead, the path to the market is rough & laden with inefficiencies from funding to licencing agreements. The bad is that almost every early stage technology at the universities has to deal with these troubles all the time.
Meanwhile we also very often hear news about the commercialization success stories of MIT, Standford, Pittsburgh, University of Texas, Washington, Colombia etc. So, while some can’t make it, some can do. What is the MAGIC?
I conducted many interviews with the experts from these universities. There is not a formula which brings success but there are well planned strategies. Although these strategies vary depending on the culture of the university & TTO, here are some very essential points to keep in mind:
Source: bit.ly/1q7nhkW
ASTP's EU Committee reflects on the relevance of the European Strategy on Research and Technology Infrastructures.
The study explores a new framework that includes 16 indicators and 41 metrics to assess how effectively EU Member…
The Commission is seeking stakeholder views on the draft for a new General Block Exemption Regulation.The State…
Join our newsletter and get the latest news